Aloxiprin
From Wikipedia, the free encyclopedia
|
Aloxiprin
|
|
| Systematic (IUPAC) name | |
| aluminum 2-acetyloxybenzoate hydroxide | |
| Identifiers | |
| CAS number | |
| ATC code | B01 |
| PubChem | |
| Chemical data | |
| Formula | C18H15O9 |
| Mol. mass | 402.288 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Aloxiprin (or aluminum acetylsalicylate) is a platelet aggregation inhibitor. It is derived from aspirin.[1]
It is also known as "Palaprin Forte".[2]
[edit] References
- ^ CUMMINGS AJ, MARTIN BK, WIGGINS LF (1963). "In vitro and in vivo properties of aloxiprin: a new aluminium derivative of acetylsalicylic acid". J. Pharm. Pharmacol. 15: 56-62. PMID 14024235.
- ^ Geller J (1968). "A comparative trial of aloxiprin ('Palaprin Forte') and phenylbutazone ('Butazolidin')". The British journal of clinical practice 22 (9): 392-4. PMID 4876729.
[edit] External links
|
||||||||||||||||||||||||||

